ClinicalTrials.gg
CompletedNCT01442064Updated Jan 10, 2012Results posted

An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)

An interventional study of Ranibizumab 0.5 mg in Macular Edema and Retinal Vein Occlusion, sponsored by Genentech, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
608
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
Largest of 91
608 · median 50
Started
2008
with 4 others
No phase
6 of 91
none open now
Registered
34th of 91
by date
Lead sponsor
7 of 91
Genentech, Inc.

Among the 91 studies testing ranibizumab in Macular Edema, this one has the largest enrollment, is one of 5 that started in 2008, is one of 6 with no phase, and was the 34th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a Genentech sponsored study (FVF2598g (NCT00056836), FVF2587g (NCT00061594), or FVF2428g (NCT00056823)). The second cohort (reported here) enrolled subjects with macular edema secondary to Retinal Vein Occlusion (RVO) who completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g (NCT00486018) or FVF4166g (NCT00485836)). Patients were enrolled within 14 days of completion of the previous study.

03

Conditions studied

  • Macular Edema
  • Retinal Vein Occlusion

Keywords

  • CNV
  • Lucentis
  • AMD
  • Age-related macular degeneration
  • RVO
  • Macular edema secondary to retinal vein occlusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form
  • The 6-month treatment and 6-month observation phases (12 months total) of a Genentech-sponsored ranibizumab study for RVO (FVF4165g or FVF4166g)
  • Expectation by the investigator that the subject may potentially benefit from intravitreal anti-vascular endothelial growth factor (VEGF) treatment

Exclusion criteria

Exclusion Criteria:

  • History of intraocular surgery (including cataract extraction, scleral buckle, etc.) within 1 month prior to Day 0 of this extension study
  • Concurrent use of systemic anti-VEGF agents
  • Use of RVO treatments not approved by the Food and Drug Administration (FDA) in the study eye
  • Use of intravitreal bevacizumab in the study eye and/or fellow eye
  • Macular edema in the study eye due to other causes than RVO such as diabetes
  • History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye
  • History of idiopathic or -associated uveitis in either eye
  • Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 30 mmHg despite treatment with antiglaucoma medication)
  • Pregnancy or lactation
  • Premenopausal women not using adequate
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications
  • Current treatment for active systemic infection
  • Inability to comply with study or follow-up procedures
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
608 participants (actual)

Study arms

  • Experimental
    Ranibizumab 0.5 mg

    Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.

    Drug: Ranibizumab 0.5 mg

Interventions

  • Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Number of Participants With Ocular Adverse Events in the Study Eye

    Number of participants with: any ocular adverse events, ocular adverse events causing treatment discontinuation, ocular serious adverse events, intraocular inflammation and cataracts that occurred in the study eye. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.

    Time frame: Up to 24 months

  2. Number of Participants With Non-ocular Adverse Events

    Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.

    Time frame: Up to 24 months

Secondary outcomes

  1. Change From Baseline in the Best Corrected Visual Acuity (BCVA)

    Change from baseline in then BCVA was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a Starting Test Distance of 4 Meters. An increase in the number of letters read indicates improvement in visual acuity.

    Time frame: Baseline (Day 0 of extension study), Months 6, 12, 18, and 24

  2. Change From Baseline in Central Foveal Thickness at Month 6 and Month 12

    Change from baseline in Central foveal (retinal) thickness was assessed by Optical Coherence Tomography (OCT). OCT was conducted at the study sites by personnel who were certified by the University of Wisconsin Fundus Photograph Reading Center.

    Time frame: Baseline (Day 0 of extension study), Months 6 and 12

  3. Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)

    NEI VFQ-25 is a 25 item questionnaire that assesses visual function and quality of life for a total possible score of 0 to 100. A higher score represents better functioning. The change from baseline is calculated at Month 12 and Month 24. Participants are grouped according to the treatment they received in initial studies FVF4165g BRAVO (NCT00486018) and FVF4166g CRUISE (NCT00485836).

    Time frame: Baseline (Day 0 of extension study), Months 12 and 24

07

Results

Posted Jan 10, 2012

Participant flow

This is an open label multi-center extension study for participants who completed FVF4165g BRAVO (NCT00486018) or FVF4166g CRUISE (NCT0048583). Cohort 2 consists of enrolled participants with macular edema secondary to retinal vein occlusion (RVO).

Participant flow — Overall Study
MilestoneRanibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)
Started971031049810799
Ranibizumab-treated subjects931031049610799
Received study drug in extension study617060708981
Completed020010
Not completed971011049810699
Withdrew: Adverse event222120
Withdrew: Death013313
Withdrew: Lost to follow-up551133
Withdrew: Physician decision112331
Withdrew: Withdrawal by subject632221
Withdrew: Sponsor decision828892889587
Withdrew: Subject non-compliance000002
Withdrew: Condition mandated other intervention112002

Outcome measures

PrimaryNumber of Participants With Ocular Adverse Events in the Study Eye

Number of participants with: any ocular adverse events, ocular adverse events causing treatment discontinuation, ocular serious adverse events, intraocular inflammation and cataracts that occurred in the study eye. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.

Time frame:
Up to 24 months
Reported as:
Number · participants
Number of Participants With Ocular Adverse Events in the Study Eye
participantsRanibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)
Any ocular adverse event (AE)516463606766
Ocular AE leading to treatment discontinuation122022
Ocular serious adverse event2465103
Intraocular inflammation000231
Cataract6106365
PrimaryNumber of Participants With Non-ocular Adverse Events

Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death. Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded. Additional information about adverse events can be found in the adverse events section.

Time frame:
Up to 24 months
Reported as:
Number · participants
Number of Participants With Non-ocular Adverse Events
participantsRanibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)
Any non-ocular adverse event567768587164
Serious non-ocular adverse event101518162120
Non-ocular adverse event led to discontinuation101010
Death013313
SecondaryChange From Baseline in the Best Corrected Visual Acuity (BCVA)

Change from baseline in then BCVA was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a Starting Test Distance of 4 Meters. An increase in the number of letters read indicates improvement in visual acuity.

Time frame:
Baseline (Day 0 of extension study), Months 6, 12, 18, and 24
Reported as:
Mean · letters
Change From Baseline in the Best Corrected Visual Acuity (BCVA)
lettersRanibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)
Month 6 (n=88,96,98,90,101,91)-0.1 ± 8.1-2.2 ± 10.5-1.3 ± 7.1-3.2 ± 10.4-4.1 ± 10.7-3.2 ± 9.7
Month 12 (n=66,66,73,58,69,50)0.9 ± 6.9-2.3 ± 11.5-0.7 ± 7.3-4.2 ± 11.3-5.2 ± 13.8-4.1 ± 12.9
Month 18 (n=23,26,32,31,26,22)0.5 ± 5.0-1.7 ± 6.3-6.1 ± 15.5-5.1 ± 14.6-6.1 ± 12.1-0.8 ± 10.9
Month 24 (n=0,2,0,0,1,0)NA ± NA-4.5 ± 16.3NA ± NANA ± NA-1.0 ± NANA ± NA
SecondaryChange From Baseline in Central Foveal Thickness at Month 6 and Month 12

Change from baseline in Central foveal (retinal) thickness was assessed by Optical Coherence Tomography (OCT). OCT was conducted at the study sites by personnel who were certified by the University of Wisconsin Fundus Photograph Reading Center.

Time frame:
Baseline (Day 0 of extension study), Months 6 and 12
Reported as:
Mean · µm
Change From Baseline in Central Foveal Thickness at Month 6 and Month 12
µmRanibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)
Month 6 (n=86,96,97,90,101,89)21.5 ± 131.636.8 ± 159.840.2 ± 117.487.4 ± 217.1161.4 ± 289.194.6 ± 235.9
Month 12 (n=62,65,72,56,69,51)3.7 ± 124.96.3 ± 163.735.3 ± 110.679.7 ± 199.488.3 ± 262.968.4 ± 252.7
SecondaryChange From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)

NEI VFQ-25 is a 25 item questionnaire that assesses visual function and quality of life for a total possible score of 0 to 100. A higher score represents better functioning. The change from baseline is calculated at Month 12 and Month 24. Participants are grouped according to the treatment they received in initial studies FVF4165g BRAVO (NCT00486018) and FVF4166g CRUISE (NCT00485836).

Time frame:
Baseline (Day 0 of extension study), Months 12 and 24
Reported as:
Mean · Scores on a scale
Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)
Scores on a scaleRanibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)
Month 12 (n=64,65,72,58,67,50)-0.3 ± 10.0-0.7 ± 9.7-0.7 ± 8.60.1 ± 10.5-1.0 ± 8.0-1.6 ± 7.7
Month 24 (n=0,2,0,0,1,0)NA ± NA6.2 ± 7.4NA ± NANA ± NA-13.3 ± NANA ± NA

Adverse events

Collected over Up to 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ranibizumab (Sham)—32/189 (16.9%)146/189 (77.2%)
Ranibizumab (0.3 mg)—49/210 (23.3%)179/210 (85.2%)
Ranibizumab (0.5 mg)—46/203 (22.7%)172/203 (84.7%)
Most frequent serious events
Showing 10 of 109
Most frequent serious events
EventRanibizumab (Sham)Ranibizumab (0.3 mg)Ranibizumab (0.5 mg)
VISUAL ACUITY REDUCEDEye disorders4/1893/2102/203
MACULAR OEDEMAEye disorders1/1892/2104/203
OSTEOARTHRITISMusculoskeletal and connective tissue disorders0/1894/2102/203
TRANSIENT ISCHAEMIC ATTACKNervous system disorders0/1894/2100/203
CARDIAC FAILURE CONGESTIVECardiac disorders1/1891/2103/203
ATRIAL FIBRILLATIONCardiac disorders2/1892/2101/203
CORONARY ARTERY DISEASECardiac disorders2/1890/2102/203
VITREOUS HAEMORRHAGEEye disorders2/1891/2100/203
FALLInjury, poisoning and procedural complications2/1891/2101/203
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders1/1890/2102/203
Most frequent other events
Showing 10 of 18
Most frequent other events
EventRanibizumab (Sham)Ranibizumab (0.3 mg)Ranibizumab (0.5 mg)
RETINAL HAEMORRHAGEEye disorders33/18954/21051/203
CONJUNCTIVAL HAEMORRHAGEEye disorders29/18937/21031/203
RETINAL VASCULAR DISORDEREye disorders19/18929/21021/203
MACULOPATHYEye disorders21/18919/21019/203
MACULAR OEDEMAEye disorders13/18923/21019/203
HYPERTENSIONVascular disorders14/18921/21015/203
NASOPHARYNGITISInfections and infestations14/18913/2108/203
RETINAL EXUDATESEye disorders11/18912/21015/203
VITREOUS DETACHMENTEye disorders9/1899/21015/203
INTRAOCULAR PRESSURE INCREASEDInvestigations9/18915/21012/203

Baseline characteristics

Age, Customized
Age, Customized(participants)Ranibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)Total
<45 years53383426
45 to <65 years433938372632215
65 to <85 years455455496859330
≥85 years478410437
Sex: Female, Male
Sex: Female, Male(Participants)Ranibizumab (Sham BRAVO)Ranibizumab (0.3 mg BRAVO)Ranibizumab (0.5 mg BRAVO)Ranibizumab (Sham CRUISE)Ranibizumab (0.3 mg CRUISE)Ranibizumab (0.5 mg CRUISE)Total
Female435746415239278
Male544658575560330
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2011
First posted
Sep 28, 2011
Start
Jul 2008
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Jan 10, 2012
Last update
Jan 10, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01442064
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Sep 28, 2011
Start date
Jul 2008
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Jan 10, 2012
Last update
Jan 10, 2012

Study contacts

Phillip Lai, M.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion